Sacubitril/valsartan and the risk of incident dementia in heart failure: a nationwide propensity-matched cohort study

Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis

(2023) Congqin Chen et al.   CNS Neuroscience & Therapeutics

Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimer’s disease model in rats

(2023) Abdallah Salah El-din Hussein et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Annual Incidence of Dementia from 2003 to 2018 in Metropolitan Seoul, Korea: A Population-Based Study

(2022) Hyuk Sung Kwon et al.   Journal of Clinical Medicine

Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality

(2022) Chenglong Li et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation

(2022) Toru Kondo et al.   EUROPEAN HEART JOURNAL

Effect of sacubitril/valsartan on cognitive impairment in colchicine‐induced Alzheimer's model in rats

(2022) Sami H. Hammadi et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2021) Theresa A McDonagh et al.   EUROPEAN HEART JOURNAL

Blood Pressure Levels and Risks of Dementia: a Nationwide Study of 4.5 Million People

(2021) Chan Joo Lee et al.   HYPERTENSION

Cognitive Decline and Risk of Dementia in Individuals With Heart Failure: A Systematic Review and Meta-analysis

(2021) SWARNA Vishwanath et al.   JOURNAL OF CARDIAC FAILURE

Evaluation of Intensive vs Standard Blood Pressure Reduction and Association With Cognitive Decline and Dementia

(2021) Caroline Dallaire-Théroux et al.   JAMA Network Open

Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients

(2020) Pradeep K. Singh et al.   NEUROBIOLOGY OF DISEASE

Twenty-seven-year time trends in dementia incidence in Europe and the United States

(2020) Frank J. Wolters et al.   NEUROLOGY

Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions

(2020) Jason Galo et al.   American Journal of Cardiovascular Drugs

Sacubitril/Valsartan

(2020) Kieran F. Docherty et al.   JACC-Heart Failure

Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database

(2018) Amichai Perlman et al.   JOURNAL OF CARDIAC FAILURE

Heart Failure as a Risk Factor for Stroke

(2018) Woohyeun Kim et al.   Journal of Stroke

The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey

(2017) Heidi A. Schoenfeld et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects

(2016) Thomas H. Langenickel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction

(2016) Jane A. Cannon et al.   EUROPEAN JOURNAL OF HEART FAILURE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer’s Disease

(2013) Marcus O. W. Grimm et al.   Frontiers in Aging Neuroscience

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

(2009) Jessie Gu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

(2009) Peter C. Austin   STATISTICS IN MEDICINE